Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.
Biozentrum and the Swiss Nanoscience Institute, University of Basel, Basel 4056, Switzerland.
EBioMedicine. 2018 Jan;27:258-274. doi: 10.1016/j.ebiom.2017.12.011. Epub 2017 Dec 13.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss. The protein HtrA1 is enriched in retinal pigment epithelial (RPE) cells isolated from AMD patients and in drusen deposits. However, it is poorly understood how increased levels of HtrA1 affect the physiological function of the RPE at the intracellular level. Here, we developed hfRPE (human fetal retinal pigment epithelial) cell culture model where cells fully differentiated into a polarized functional monolayer. In this model, we fine-tuned the cellular levels of HtrA1 by targeted overexpression. Our data show that HtrA1 enzymatic activity leads to intracellular degradation of tubulin with a corresponding reduction in the number of microtubules, and consequently to an altered mechanical cell phenotype. HtrA1 overexpression further leads to impaired apical processes and decreased phagocytosis, an essential function for photoreceptor survival. These cellular alterations correlate with the AMD phenotype and thus highlight HtrA1 as an intracellular target for therapeutic interventions towards AMD treatment.
年龄相关性黄斑变性(AMD)是导致不可逆性视力丧失的主要原因。在从 AMD 患者中分离的视网膜色素上皮(RPE)细胞和玻璃膜疣沉积物中,富含 HtrA1 蛋白。然而,人们对 HtrA1 水平升高如何影响 RPE 的细胞内生理功能知之甚少。在这里,我们开发了 hfRPE(人胎儿视网膜色素上皮)细胞培养模型,其中细胞完全分化为极化的功能单层。在这种模型中,我们通过靶向过表达来精细调节 HtrA1 的细胞水平。我们的数据表明,HtrA1 的酶活性导致微管的细胞内降解,微管数量相应减少,从而导致细胞机械表型发生改变。HtrA1 的过表达进一步导致顶突过程受损和吞噬作用减少,而吞噬作用是光感受器存活的重要功能。这些细胞改变与 AMD 表型相关,因此强调 HtrA1 是针对 AMD 治疗的治疗干预的细胞内靶标。